Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer - Concepedia

Concepedia

Publication | Open Access

Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer

DOI Full Paper Access

772

Citations

17

References

2004

Year

Eric Van Cutsem, Helgi van de Velde, Petr Karásek, Helmut Oettle, Walter L. Vervenne, Patrick Schöffski, Stephanie Post, Chris Verslype, H Neumann, Howard Safran,

Journal of Clinical Oncology

Abstract

The combination of gemcitabine and tipifarnib has an acceptable toxicity profile but does not prolong overall survival in advanced pancreatic cancer compared with single-agent gemcitabine.

References

	Year	Citations

Page 1